Publications
5600 Results
- Journal / Conference
- J Clin Oncol 35, 2017 (suppl; abstr 7503); American Society of Clinical OncologyAnnual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
- Year
- 2017
- Research Committee(s)
- Leukemia
- Study Number(s)
- C10404
A genetic risk-stratified, phase II study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): final results of Cancer and Leukemia Group B (CALGB) 10404
- Journal / Conference
- Annals of Oncology 28 (suppl_2): mdx091.003; European Lung Cancer Conference (May 5-7, 2017, Geneva, Switzerland), oral presentation
- Year
- 2017
- Research Committee(s)
- Lung
- Study Number(s)
- S1400A
A phase II study of Durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A
- Journal / Conference
- J Clin Oncol 35 (suppl; abstr 9054); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
- Year
- 2017
- Research Committee(s)
- Lung
- Study Number(s)
- S1400B
A phase II study of gdc-0032 (taselisib) for previously treated pi3k positive patients with stage iv squamous cell lung cancer (sqNSCLC): lung-map sub-study swog s1400B
- Journal / Conference
- J Clin Oncol 35 (suppl; abstr 9056); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
- Year
- 2017
- Research Committee(s)
- Lung
- Study Number(s)
- S1400C
A phase II study of palbociclib (p) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (scc): lung-map sub-study swog S1400C
- Journal / Conference
- J Clin Oncol 35, 2017 (suppl; abstr 2578); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
- Year
- 2017
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1221
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173)
- Journal / Conference
- J Clin Oncol 35, 2017 (suppl; abstr 10093);American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster
- Year
- 2017
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S0715
Two-year trends and predictors of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715; NCT00775645) (http://abstracts.asco.org/199/AbstView_199_184547.html)
- Journal / Conference
- J Clin Oncol 35, 2017 (suppl; abstr 9500); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presenation
- Year
- 2017
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-a2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms
- Journal / Conference
- J Clin Oncol 35 (suppl; abstr 9055); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
- Year
- 2017
- Research Committee(s)
- Lung
- Study Number(s)
- S1400D
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGFR pathway-activated stage IV squamous cell lung cancer (sqNSCLC): lung-map sub-study SWOG S1400D
- Journal / Conference
- Journal of Clinical Oncology Mar 10;35(8):885-892
- Year
- 2017
- Research Committee(s)
- Melanoma
- PMID
- PMID28135150
- PMC
- PMC5455684
- Study Number(s)
- CTSU/E1697
Phase III randomized study of 4 weeks of high-dose interferon-a-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697)
- Journal / Conference
- Journal of Thoracic Oncology Aug;12(8):1299-1308; Jun 6 [Epub ahead of print]
- Year
- 2017
- Research Committee(s)
- Lung
- PMID
- PMID28599887;PMC5690479
- Study Number(s)
- S0905